

JUL 10 2006

PATENT &amp; TRADEMARK OFFICE

U.S. PATENT &amp; TRADEMARK OFFICE

JUL 11 2006

PATENT &amp; TRADEMARK OFFICE

U.S. PATENT &amp; TRADEMARK OFFICE

This listing of the claims will replace all prior versions, and listings, of claims in this application.

- CANCELED** JUL 11 2006  
PATENT & TRADEMARK OFFICE  
U.S. PATENT & TRADEMARK OFFICE
- AMENDMENTS TO THE CLAIMS**
1. **(Original)** A method of inhibiting expression of a target allele in a cell comprising at least two different alleles of a gene, the method comprising administering to the cell an siRNA specific for the target allele.
  2. **(Original)** The method of claim 1, wherein the target allele is correlated with a disorder associated with a dominant gain of function mutation.
  3. **(Original)** The method of claim 2, wherein the disorder is selected from the group of amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease.
  4. **(Original)** A method of treating a subject having a disorder correlated with the presence of a dominant gain of function mutant allele, the method comprising administering to the subject a therapeutically effective amount of an siRNA specific for the mutant allele.
  5. **(Original)** The method of claim 4, wherein the siRNA is targeted to the gain of function mutation.
  6. **(Original)** The method of claim 4, wherein the disorder is selected from the group of amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease.
  7. **(Original)** The method of claim 4 wherein the disease is amyotrophic lateral sclerosis.
  8. **(Original)** The method of claim 7 wherein the allele is SOD1.

9. **(Original)** The method of claim 8, wherein the mutant allele comprises a point mutation.

10. **(Original)** The method of claim 8, wherein the point mutation is a guanine: cytosine mutation.

11. **(Original)** The method of claim 8, wherein the mutation is G256C.

12. **(Original)** The method of claim 8, wherein the mutation is G281C.

13. **(Currently Amended)** The method of claim 8, wherein the siRNA comprises a sequence as set forth in Figure 1A is selected from the group consisting of:

- (a) a mutant siRNA P11 comprising (i) a sense strand sequence set forth as SEQ ID NO: 5 and (ii) an anti-sense strand sequence set forth as SEQ ID NO: 6;
- (b) a mutant siRNA P10 comprising (i) a sense strand sequence set forth as SEQ ID NO: 3; and (ii) an anti-sense strand sequence set forth as SEQ ID NO: 4; and
- (c) a mutant siRNA P9 comprising (i) a sense strand sequence set forth as SEQ ID NO: 1; and (ii) an anti-sense strand sequence as set forth as SEQ ID NO: 2.

14. **(Cancelled)**

15. **(Cancelled)**

16. **(Cancelled)**


17. **(Cancelled)**

18. **(Cancelled)**

19. **(Cancelled)**

20. **(Cancelled)**

21. **(New)** The method of claim 8, wherein the siRNA is a mutant siRNA P11 comprising (i) a sense strand sequence set forth as SEQ ID NO: 5; and (ii) an anti-sense strand sequence set forth as SEQ ID NO: 6.
22. **(New)** The method of claim 8, wherein the siRNA is a mutant siRNA P10 comprising (i) a sense strand sequence set forth as SEQ ID NO: 3; and (ii) an anti-sense strand sequence set forth as SEQ ID NO: 4.
23. **(New)** The method of claim 8, wherein the siRNA is a mutant siRNA P9 comprising (i) a sense strand sequence set forth as SEQ ID NO: 1; and (ii) an anti-sense strand sequence set forth as SEQ ID NO: 2.
24. **(New)** The method of claim 8, wherein the siRNA is administered to cell in the form of a shRNA, wherein the shRNA is cleaved in the cell to generate the siRNA.
25. **(New)** The method of claim 24, wherein the shRNA is a G93A SOD1 shRNA.
26. **(New)** The method of claim 25, wherein the G93A SOD1 shRNA has the sequence set forth as SEQ ID NO: 16.
27. **(New)** The method of claim 24, wherein the shRNA is expressed from an expression construct.



Application No.: 10/700,816 10 2006

Docket No.: UMY-038

**AMENDMENTS TO THE SEQUENCE LISTING**

Please replace the originally filed Sequence Listing with the enclosed substitute Sequence Listing.

The substitute Sequence Listing now contains the following amendments:

SEQ ID NOS 1-6 and 9-14 have been replaced with new SEQ ID NOS 1-6 and 9-14.